InSys Therapeutics, Inc. (Inactive) (extinct)

InSys Therapeutics, Inc. (Inactive) (extinct)

InSys Therapeutics, Inc. (Inactive) (extinct)

Date Founded



10220 South 51st Street,Suite 2,Phoenix, AZ 85044

Type of Company




Company Description

InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ.

Executives & Employees

Vice President-Business Development & Strategic Planning

Paths to InSys Therapeutics, Inc. (Inactive)
Potential Connections via
Relationship Science
InSys Therapeutics, Inc. (Inactive)
Recent Transactions
Details Hidden

NeoPharm, Inc. purchases InSys Therapeutics, Inc. (Inactive)

Transaction Advisors
Legal Advisor

Advised onNeoPharm, Inc. purchases InSys Therapeutics, Inc. (Inactive)

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by InSys Therapeutics, Inc. (Inactive). The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of InSys Therapeutics, Inc. (Inactive)'s profile does not indicate a business or promotional relationship of any kind between RelSci and InSys Therapeutics, Inc. (Inactive).